<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/3a118701-a82b-4462-a7d1-4b20bf0854b7/ryan-board-room.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="2752" height="1664" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/3a118701-a82b-4462-a7d1-4b20bf0854b7/ryan-board-room.png"/></p>
<p>新泽西州沃伦，2025 年 12 月 19 日（全球新闻稿）——Tevogen（“Tevogen Bio Holdings Inc.” 或 “公司”）（纳斯达克：TVGN）今天宣布，其创始人兼首席执行官 Ryan Saadi 博士已向 Mt. Bethel 消防公司捐赠了 50,000 股个人持有的 Tevogen 普通股，以支持该组织保护沃伦镇社区的使命。这些捐赠反映了 Saadi 博士对支持第一响应者和沃伦镇社区的持续承诺。</p>
<p>“我代表 Mt. Bethel 消防公司，衷心感谢 Saadi 博士的慷慨捐赠。这一支持将帮助增强我们的准备能力，并提升我们成员在安全有效地服务沃伦镇社区时所依赖的设备和资源，” Mt. Bethel 消防公司的助理主任 Derek Reedman 评论道。</p>
<p>“我很高兴能够直接支持沃伦镇社区和每天为其服务的第一响应者。在这里建立 Tevogen 一直是有意为之，不仅是为了推动重要科学的发展，也是为了创造有意义的工作和长期的经济影响，” Tevogen 创始人兼首席执行官 Ryan Saadi 补充道。“从一个概念开始，已经发展成为一家估值约为 100 亿美元的公司，并通过商业化确保了现金流。更重要的是，这是一个有潜力为目前仍然大部分无法治疗的疾病提供解决方案的平台。支持这一工作的社区既是责任也是特权。”</p>
<p>所捐赠的股份旨在支持 Mt. Bethel 消防公司的倡议，以增强安全性、准备能力和应急响应能力。此次捐赠是根据 SEC 第 144 条规则进行的，Saadi 博士将不会从证券处置中获得任何收益。</p>
<p><strong>关于 Tevogen</strong></p>
<p>Tevogen 是一家基于可负担性、效率和科学严谨性原则构建的下一代社会整合医疗企业。该公司利用行业领先的人工智能和精准 T 细胞治疗平台，以患者为中心和成本控制的运营模式，以及与全球技术领导者的战略合作，支持在多个治疗领域开发先进的、拯救生命的疗法和可扩展的解决方案，以改善更广泛的医疗保健系统。</p>
<p>Tevogen Bio 是公司的主要项目，已完成一项概念验证临床试验，证明其单 HLA 限制、基因未修饰的异体 T 细胞的潜力。Tevogen Bio 的产品线涵盖病毒学、肿瘤学和神经学，基于公司的专有 ExacTcell™平台构建。</p>
<p>Tevogen.AI 旨在通过加速目标检测、帮助降低失败率和支持优化临床试验设计来变革药物开发，采用专有的预测技术。该平台利用来自领先技术提供商（包括微软和 Databricks）的云和数据服务，以推进其长期目标，即预测任何给定蛋白质-HLA 组合的蛋白质组，从而实现快速和成本高效的治疗发现。</p>
<p>Tevogen 正在探索未来的战略举措，可能包括国内仿制药、生物类似药、医疗设备和创新保险解决方案，以支持医疗服务提供者。这些项目共同反映了 Tevogen 的使命，即通过更快、更高效和更公平的医疗模式推动可持续创新，扩大患者的获取渠道。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含某些前瞻性声明，包括但不限于与 Tevogen 的研究和制造能力的计划、对未来增长的预期、对医疗保健和生物制药行业的预期，以及 Tevogen 对其产品候选者在治疗传染病和癌症方面的开发、潜在益处和患者获取的预期。前瞻性声明有时可以通过诸如 “可能”、“可以”、“将”、“期望”、“预期”、“可能”、“潜在”、“目标”、“机会”、“项目”、“相信”、“未来” 等词语及其反义词来识别。这些声明基于管理层截至本新闻稿日期的期望、假设、估计、预测和信念，并受到许多因素的影响，包括已知和未知的风险、延迟、不确定性以及其他不在公司控制范围内的因素，这些因素可能导致公司的实际结果、表现或成就与这些前瞻性声明所表达或暗示的结果、表现或其他期望存在重大差异。</p>
<p>可能导致实际结果、表现或成就与前瞻性声明中所表达或暗示的内容不同的因素包括但不限于：Tevogen 所竞争市场的变化，包括其竞争格局、技术演变或监管变化；国内和全球经济状况的变化；Tevogen 可能无法执行其增长战略或在管理增长和扩展运营方面遇到困难的风险；Tevogen 可能无法开发和维持有效内部控制的风险；未能实现 Tevogen 的商业化和发展计划以及识别和实现额外机会的风险，这可能受到竞争、Tevogen 经济增长和管理增长的能力以及招聘和留住关键员工等因素的影响；Tevogen 可能未能跟上快速技术发展的步伐，以提供新的和创新的产品和服务，或在不成功的新产品和服务上进行大量投资的风险；Tevogen 需要筹集额外资金以充分实现其商业计划的风险；与开发、许可或收购新疗法相关的风险；与 Tevogen 业务相关的监管诉讼或程序的风险；在执行、成本和完成临床前研究和临床试验中固有的不确定性；与监管审查、批准和商业开发相关的风险；与知识产权保护相关的风险；Tevogen 有限的运营历史；以及在 Tevogen 的 10-K 表格年度报告和随后向 SEC 提交的文件中讨论或引用的那些因素。</p>
<p>您不应对前瞻性声明过度依赖，这些声明仅在作出时有效。Tevogen 没有义务更新任何前瞻性声明，除非适用法律要求。</p>
<p><strong>联系方式</strong></p>
<p>Tevogen Bio 公共关系部</p>
<p>电话：1 877 TEVOGEN，分机 701</p>
<p>Communications@Tevogen.com</p>
<p>与本公告一起发布的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/3a118701-a82b-4462-a7d1-4b20bf0854b7 获取</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05USXhNQ00zTXpNd09EUTRJekl5T0RrNU1UYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05USXhNQ00zTXpNd09EUTRJekl5T0RrNU1UYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTZmYTJjMDUtMjk3Yi00MGYwLTk3OGQtM2ZkODU0MTBiMzFmLTEzMDE0NjctMjAyNS0xMi0xOS1lbg==/tiny/Tevogen-Bio-Inc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTZmYTJjMDUtMjk3Yi00MGYwLTk3OGQtM2ZkODU0MTBiMzFmLTEzMDE0NjctMjAyNS0xMi0xOS1lbg==/tiny/Tevogen-Bio-Inc.png"/></p>

TVGN

<p>Tevogen 首席执行官 Ryan Saadi 博士向 Mt. Bethel 消防公司捐赠了 50,000 股个人股份，以支持他们在沃伦镇的使命。这笔捐赠体现了他对第一响应者和社区的承诺。这些股份将增强消防公司的安全和应急响应能力。该捐赠是在 SEC 第 144 条规则下进行的，Saadi 博士没有获得任何收益。Tevogen 是一家专注于可负担、高效和先进疗法的医疗企业，利用人工智能和精准 T 细胞疗法平台</p>

<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/3a118701-a82b-4462-a7d1-4b20bf0854b7/ryan-board-room.png" alt="" original-src="https://ml.globenewswire.com/Resource/Download/3a118701-a82b-4462-a7d1-4b20bf0854b7/ryan-board-room.png"/></p>
<p>WARREN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 50,000 shares of his personal holdings of Tevogen common stock to the Mt. Bethel Fire Company, supporting the organization’s mission to protect the Warren Township community. The donations reflect Dr. Saadi’s continued commitment to supporting first responders and the Warren Township community.</p>
<div class="lb-trans"><p>新泽西州沃伦，2025 年 12 月 19 日（全球新闻稿）——Tevogen（“Tevogen Bio Holdings Inc.” 或 “公司”）（纳斯达克：TVGN）今天宣布，其创始人兼首席执行官 Ryan Saadi 博士已向 Mt. Bethel 消防公司捐赠了 50,000 股个人持有的 Tevogen 普通股，以支持该组织保护沃伦镇社区的使命。这些捐赠反映了 Saadi 博士对支持第一响应者和沃伦镇社区的持续承诺。</p>
</div><p>“On behalf of the Mt. Bethel Fire Company, we’re sincerely grateful to Dr. Saadi for this generous donation. This support will help strengthen our readiness and enhance the equipment and resources our members rely on to serve the Warren Township community safely and effectively,” commented Assistant Chief, Derek Reedman, Mt. Bethel Fire Company.</p>
<div class="lb-trans"><p>“我代表 Mt. Bethel 消防公司，衷心感谢 Saadi 博士的慷慨捐赠。这一支持将帮助增强我们的准备能力，并提升我们成员在安全有效地服务沃伦镇社区时所依赖的设备和资源，” Mt. Bethel 消防公司的助理主任 Derek Reedman 评论道。</p>
</div><p>“I’m pleased to be able to directly support the Warren Township community and the first responders who serve it every day. Building Tevogen here has always been intentional, not only to advance important science, but to create meaningful jobs and long-term economic impact locally,” added Ryan Saadi, Founder and CEO, Tevogen. “What began as a concept has evolved into a company with an estimated $10 billion asset valuation and a secured cash runway through commercialization. More importantly, it is a platform with the potential to deliver solutions for diseases that remain largely untreatable today. Supporting the community where this work is being built is both a responsibility and a privilege.”</p>
<div class="lb-trans"><p>“我很高兴能够直接支持沃伦镇社区和每天为其服务的第一响应者。在这里建立 Tevogen 一直是有意为之，不仅是为了推动重要科学的发展，也是为了创造有意义的工作和长期的经济影响，” Tevogen 创始人兼首席执行官 Ryan Saadi 补充道。“从一个概念开始，已经发展成为一家估值约为 100 亿美元的公司，并通过商业化确保了现金流。更重要的是，这是一个有潜力为目前仍然大部分无法治疗的疾病提供解决方案的平台。支持这一工作的社区既是责任也是特权。”</p>
</div><p>The contributed shares are intended to support Mt. Bethel Fire Company initiatives that enhance safety, readiness, and emergency response capabilities. The donation was conducted in accordance with SEC Rule 144 and Dr. Saadi will not receive any proceeds from the disposal of the securities.</p>
<div class="lb-trans"><p>所捐赠的股份旨在支持 Mt. Bethel 消防公司的倡议，以增强安全性、准备能力和应急响应能力。此次捐赠是根据 SEC 第 144 条规则进行的，Saadi 博士将不会从证券处置中获得任何收益。</p>
</div><p><strong>About Tevogen</strong></p>
<div class="lb-trans"><p><strong>关于 Tevogen</strong></p>
</div><p>Tevogen is a next-generation, socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages industry-leading artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and strategic engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.</p>
<div class="lb-trans"><p>Tevogen 是一家基于可负担性、效率和科学严谨性原则构建的下一代社会整合医疗企业。该公司利用行业领先的人工智能和精准 T 细胞治疗平台，以患者为中心和成本控制的运营模式，以及与全球技术领导者的战略合作，支持在多个治疗领域开发先进的、拯救生命的疗法和可扩展的解决方案，以改善更广泛的医疗保健系统。</p>
</div><p>Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA–restricted, genetically unmodified allogeneic T cells. The Tevogen Bio pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.</p>
<div class="lb-trans"><p>Tevogen Bio 是公司的主要项目，已完成一项概念验证临床试验，证明其单 HLA 限制、基因未修饰的异体 T 细胞的潜力。Tevogen Bio 的产品线涵盖病毒学、肿瘤学和神经学，基于公司的专有 ExacTcell™平台构建。</p>
</div><p>Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.</p>
<div class="lb-trans"><p>Tevogen.AI 旨在通过加速目标检测、帮助降低失败率和支持优化临床试验设计来变革药物开发，采用专有的预测技术。该平台利用来自领先技术提供商（包括微软和 Databricks）的云和数据服务，以推进其长期目标，即预测任何给定蛋白质-HLA 组合的蛋白质组，从而实现快速和成本高效的治疗发现。</p>
</div><p>Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.</p>
<div class="lb-trans"><p>Tevogen 正在探索未来的战略举措，可能包括国内仿制药、生物类似药、医疗设备和创新保险解决方案，以支持医疗服务提供者。这些项目共同反映了 Tevogen 的使命，即通过更快、更高效和更公平的医疗模式推动可持续创新，扩大患者的获取渠道。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.</p>
<div class="lb-trans"><p>本新闻稿包含某些前瞻性声明，包括但不限于与 Tevogen 的研究和制造能力的计划、对未来增长的预期、对医疗保健和生物制药行业的预期，以及 Tevogen 对其产品候选者在治疗传染病和癌症方面的开发、潜在益处和患者获取的预期。前瞻性声明有时可以通过诸如 “可能”、“可以”、“将”、“期望”、“预期”、“可能”、“潜在”、“目标”、“机会”、“项目”、“相信”、“未来” 等词语及其反义词来识别。这些声明基于管理层截至本新闻稿日期的期望、假设、估计、预测和信念，并受到许多因素的影响，包括已知和未知的风险、延迟、不确定性以及其他不在公司控制范围内的因素，这些因素可能导致公司的实际结果、表现或成就与这些前瞻性声明所表达或暗示的结果、表现或其他期望存在重大差异。</p>
</div><p>Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.</p>
<div class="lb-trans"><p>可能导致实际结果、表现或成就与前瞻性声明中所表达或暗示的内容不同的因素包括但不限于：Tevogen 所竞争市场的变化，包括其竞争格局、技术演变或监管变化；国内和全球经济状况的变化；Tevogen 可能无法执行其增长战略或在管理增长和扩展运营方面遇到困难的风险；Tevogen 可能无法开发和维持有效内部控制的风险；未能实现 Tevogen 的商业化和发展计划以及识别和实现额外机会的风险，这可能受到竞争、Tevogen 经济增长和管理增长的能力以及招聘和留住关键员工等因素的影响；Tevogen 可能未能跟上快速技术发展的步伐，以提供新的和创新的产品和服务，或在不成功的新产品和服务上进行大量投资的风险；Tevogen 需要筹集额外资金以充分实现其商业计划的风险；与开发、许可或收购新疗法相关的风险；与 Tevogen 业务相关的监管诉讼或程序的风险；在执行、成本和完成临床前研究和临床试验中固有的不确定性；与监管审查、批准和商业开发相关的风险；与知识产权保护相关的风险；Tevogen 有限的运营历史；以及在 Tevogen 的 10-K 表格年度报告和随后向 SEC 提交的文件中讨论或引用的那些因素。</p>
</div><p>You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.</p>
<div class="lb-trans"><p>您不应对前瞻性声明过度依赖，这些声明仅在作出时有效。Tevogen 没有义务更新任何前瞻性声明，除非适用法律要求。</p>
</div><p><strong>Contacts</strong></p>
<div class="lb-trans"><p><strong>联系方式</strong></p>
</div><p>Tevogen Bio Communications</p>
<div class="lb-trans"><p>Tevogen Bio 公共关系部</p>
</div><p>T: 1 877 TEVOGEN, Ext 701</p>
<div class="lb-trans"><p>电话：1 877 TEVOGEN，分机 701</p>
</div><p>Communications@Tevogen.com</p>
<div class="lb-trans"><p>Communications@Tevogen.com</p>
</div><p>A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3a118701-a82b-4462-a7d1-4b20bf0854b7</p>
<div class="lb-trans"><p>与本公告一起发布的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/3a118701-a82b-4462-a7d1-4b20bf0854b7 获取</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05USXhNQ00zTXpNd09EUTRJekl5T0RrNU1UYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwNTIxMCM3MzMwODQ4IzIyODk5MTc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTZmYTJjMDUtMjk3Yi00MGYwLTk3OGQtM2ZkODU0MTBiMzFmLTEzMDE0NjctMjAyNS0xMi0xOS1lbg==/tiny/Tevogen-Bio-Inc.png" alt="" original-src="https://ml.globenewswire.com/media/MTZmYTJjMDUtMjk3Yi00MGYwLTk3OGQtM2ZkODU0MTBiMzFmLTEzMDE0NjctMjAyNS0xMi0xOS1lbg==/tiny/Tevogen-Bio-Inc.png"/></p>

Tevogen 首席执行官捐赠个人股份以支持当地消防部门 | TVGN 股票新闻